PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 226 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2022:... June 5, 2022 In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in... March 10, 2026 6 of the biggest good news cancer stories of 2021 December 15, 2021 Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling... March 21, 2019 Load more HOT NEWS Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... Woman’s Doctors Kept Telling Her She Was ‘Just Overweight,’ Ended Up...
